

06 July 2023

Our Ref: RFI 50738

Dear

**Freedom of Information Act 2000
Information in Relation to Chronic Lymphocytic Leukaemia**

I am writing to confirm that the South Eastern Health & Social Care Trust (the Trust) has now completed its search for information relating to the above which you requested on 02 May 2023. Please accept my apologies for the delay in responding to your request. Thank you for your understanding and forbearance.

A response to each of the questions raised has been provided by the Hospital Services Directorate and is attached in Appendix A.

If you are unhappy as to how this request has been handled, you have the right to seek a review within the Trust in the first instance. You should write to the Information Governance Department, Lough House, Ards Community Hospital (informationgovernance@setrust.hscni.net) within two months of the date of this response and your complaint will be considered and a response provided, within 20 working days of receipt.

If, after receiving a response, you remain unhappy, you can refer your complaint to the Information Commissioner at The Information Commissioner's Office –Northern Ireland, 3rd Floor, 14 Cromac Place, Belfast, BT7 2JB. It is important to note that if you refer any matter to the Information Commissioner, you will need to show evidence of having gone through the Trust's internal review procedure to try to resolve the matter with the Trust in the first instance.

If you have any queries about this letter, please do not hesitate to contact me. Please remember to quote the reference number above in any future communications.

Yours sincerely

**Robyn Watterson
Information Governance Officer**

Q1. How many patients has your Organisations treated in the past 3 months for Chronic Lymphocytic Leukaemia (CLL)? In case you do not treat CLL, which other Organisation do you refer needing treatment to?

A1. The information requested is not held on a central information system. To obtain this information would require a manual review of records. This would exceed the 'Appropriate Limit' as defined by the Freedom of Information Act 2000. The Trust therefore exempts the release of this information under Section 21 (1).

12(1) Section (1) does not oblige a public authority to comply with a request for information if the authority estimates that the cost of complying with the request would exceed the appropriate limit.

In accordance with the Freedom of Information Act 2000, this statement acts as a refusal notice.

However 2 patients have been diagnosed within the past 3 months.

Q2. How many Chronic Lymphocytic Leukaemia (CLL) patients have been treated in the past 3 months with the following:

- **BR (bendamustine + rituximab)**
- **Calquence (acalabrutinib)**
- **FCR (fludarabine + cyclophosphamide + rituximab)**
- **Gazyva (obinutuzumab) + chlorambucil**
- **Imbruvica (ibrutinib)**
- **Venclexta (venetoclax)**
- **Venclexta (venetoclax) + Gazyva (obinutuzumab)**
- **Venclexta (venetoclax) + rituximab**
- **Zydelig (idelalisib) + rituximab**
- **Any other systemic anti-cancer therapy**
- **Wait and watch (monitoring only, no active treatment)**

A2.

Treatment	Number of Patients Treated
BR (bendamustine + rituximab)	Nil
Calquence (acalabrutinib)	Nil
FCR (fludarabine + cyclophosphamide + rituximab)	Nil
Gazyva (obinutuzumab) + chlorambucil	Nil

Imbruvica (ibrutinib)	6
Venclexta (venetoclax)	8
Venclexta (venetoclax) + Gazyva (obinutuzumab)	Nil
Venclexta (venetoclax) + rituximab	1
Zydelig (idelalisib) + rituximab	Nil
Any other systemic anti-cancer therapy	Nil
Wait and watch (monitoring only, no active treatment)	Nil

Q3. *If your organisation does treat Chronic Lymphocytic Leukaemia, do you currently participate in any ongoing clinical trials for the treatment of CLL? If so, can you please provide the name of each trial along with the number of patients taking part?*

A3. There are currently no clinical trials open within the Trust for Chronic Lymphocytic Leukaemia.